DOSEGUY

Thozalinone

guinea pig

Also seen as: Stimsen, CL-39808, Tozalinone, thoz

The Dose Guy’s verdict
Sep 1, 2026
1 source

Thozalinone is a 1960s stimulant that nobody remembers for a reason. It was tested in depression and obesity trials that left no readable results behind them, and the only surviving literature is mouse pharmacology from the 1980s. The nootropic fringe has picked it up as a research chemical because it is a dopaminergic stimulant you can buy, not because the evidence supports it. If you want a stimulant with actual data, tranylcypromine is the real drug on this shelf, with decades of clinical evidence, if you can handle the restrictions it demands. If you want a lighter experiment, there are better experiments elsewhere on the list.

Would I take it?Caution, almost nothing behind it.

What it is

A dopaminergic stimulant from the oxazolidine family, related to pemoline. Thozalinone was developed as a mild stimulant antidepressant in the mid-20th century, briefly studied, and abandoned. What little pharmacology exists shows it drives dopamine-mediated gnawing behavior in mice, the signature the investigators used to call it a dopaminergic stimulant. In the lab, acid hydrolysis converts thozalinone, pemoline, and fenozolone to the same core compound for detection purposes, which is an analytical relationship, not proof they share a metabolic pathway in a person.

On the nootropic shelf it sits in the deep tail: a research chemical that people source because it exists and is cheap, not because anyone has made a case for it. Tranylcypromine is the real drug in this corner of the shelf, with decades of clinical evidence behind it, if you are willing to handle the restrictions it demands.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The evidence barely exists. Two human studies were published decades ago, but neither left an abstract with results, so the actual findings are inaccessible.

In a neuroleptic-withdrawal experiment, thozalinone at 50 mg/kg elicited dopamine-mediated gnawing in 80 to 100% of mice withdrawn from classical antipsychotics, versus 50% of controls. Pharmacology, not efficacy.Psychopharmacology 1981 · mouse model
A controlled depression trial and an obesity clinical report exist in PubMed, but neither provides an abstract reporting outcomes. The human data is literally unreadable.as of Aug 2026
No PubMed abstract reports adverse-event rates, pharmacokinetics, or any other human safety or tolerability data for thozalinone.as of Aug 2026

Realistic protocols

I am not building a protocol out of 1980s mouse gnawing data and two human trials with no accessible results. For the record, forum lore runs thozalinone at roughly 100 to 300 mg orally, once or twice daily, as an energy and focus compound. That is lore, not evidence: nobody has measured absorption, duration, or a dose-response curve in a person. If you run it anyway, go low, keep it short, and do not combine it with other dopaminergic compounds without understanding the additive risk. Dose early in the day, the same as any stimulant. In mice, alcohol increased thozalinone-elicited dopaminergic behavior, so drinking on it is an unknown you should not test casually. Log what you take and what you notice.

Side effects

No human side-effect data exists. What follows is inference from the mechanism and forum reports:

anecdotalStimulant-class effects: restlessness, elevated heart rate, appetite suppression, difficulty sleeping if dosed late.
anecdotalIrritability or edginess at higher doses, the dopaminergic push overshooting.
unknownNo human safety data of any kind. A dopaminergic stimulant with zero tolerability data earns real caution, especially around cardiovascular load and dependence potential.

Where to buy

No live listings from tracked vendors right now.